News and Press Releases
WuXi Vaccines Wins Second Consecutive ‘Best Vaccine CMO Award’ at AVEA 2023
13 December 2023 – Singapore – WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organisation (CDMO), was named ‘Best Vaccine CMO of the Year’ for the second consecutive...
Category: BioManufacturing, Drug Delivery, Drug Discovery
Posted: December 13, 2023
ViroCell signs manufacturing services agreement with UCL to accelerate research into prevention of relapse in childhood blood cancer
Agreement will leverage ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia 12 December 2023 -- London, UK and...
Category: BioManufacturing
Posted: December 12, 2023
SolasCure demonstrates proof-of-concept in phase 2a safety trial of Aurase Wound Gel
Phase 2a clinical trial evaluated Aurase Wound Gel in patients with venous leg ulcers Former Smith+Nephew CMO Andy Weymann joins as chairman to support progression of further phase 2 clinical...
Category: Clinical Trials
Posted: December 12, 2023
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers
At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...
Category: Clinical Trials
Posted: December 12, 2023
Scottish Medicines Consortium accepts Sotyktu(deucravacitinib) for NHS use in certain adults with moderate to severe plaque psoriasis
Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic...
Category: Pharmaceutical
Posted: December 11, 2023
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84% at 54 Months in Patients with Chronic Lymphocytic Leukaemia
Additional data from the phase 2 CAPTIVATE study, show 82% of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line treatment...
Category: Clinical Trials
Posted: December 11, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Evonetix Announces Agreement for Revolutionary Gene Synthesis Platform with Analog Devices
The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions...
Category: BioManufacturing
Posted: December 7, 2023
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
7 December 2023 – Laupheim, Milford, MA, USA, and Stevenage, UK – Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products...
Category: BioManufacturing, Drug Discovery
Posted: December 7, 2023
RSSL announces new state-of-the-art facility opening as part of ambitious expansion plan.
28 November 2023 – Reading, UK — RSSL, a cutting-edge food and pharmaceutical contract research organisation, today announced the opening of its new state-of-the-art analytical testing facility on the University...
Category: BioManufacturing, Manufacturing and Packing
Posted: December 6, 2023
Reading Scientific Services Ltd. Reading Science Centre Whiteknights Campus Pepper Lane Reading, Berkshire RG6 6LA, United Kingdom
Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
4 December 2023 – Laupheim, Germany – Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Dr...
Category: BioManufacturing, Pharmaceutical
Posted: December 4, 2023
Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
Published in The Lancet, results of the randomised phase 3 BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint inhibitor atezolizumab to standard of care with bevacizumab and chemotherapy...
Category: Clinical Trials, Drug Delivery
Posted: December 4, 2023
C/ Natzaret, 115-117 08035 – BARCELONA – Spain
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
30 November 2023 -- Bengaluru, India -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully...
Category: Pharmaceutical
Posted: November 30, 2023
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level...
Category: Drug Discovery
Posted: November 27, 2023
